Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb 27:5:111-6.
doi: 10.2147/DDDT.S5392.

Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine

Lilliana Oliveira  1 , Russell D Cohen
Affiliations
Review

Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine

Lilliana Oliveira et al. Drug Des Devel Ther. .

Abstract

The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the first once daily mesalamine product approved by the Food and Drug Administration for the maintenance of UC remission. This review will examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, and discuss the potential role of improving medication compliance and decreasing costs in UC maintenance.

Keywords: 5-ASA; adherence; compliance; costs; mesalamine; quality of life; ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean luminal pH measurement in 10 patients with active ulcerative colitis.
Figure 2
Figure 2
Clinical remission rates at 8 weeks in 321 patients with active mild-to-moderate ulcerative colitis to three different daily doses of granulated extended-release mesalamine.
Figure 3
Figure 3
Annual average per-patient 1-year health care costs (US$) in 1693 ulcerative colitis patients captured in a large health insurance claims database.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424–1429. - PubMed
    1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004 Sep;53(Suppl 5):V1–V16. - PMC - PubMed
    1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000;95(12):3452–3457. - PubMed
    1. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol. 2000;95(12):3343–3345. - PubMed
    1. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88(8):1188–1197. - PubMed

MeSH terms